Last updated: 2026-09-06 03:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Eledon Pharmaceuticals, Inc. (ELDN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.02, with a market capitalization of $242.97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.35 to $4.60. This page covers its latest market performance, valuation, price trends and company information.
$242.97M | |
$2.98 | |
$22.91 | |
$1.07 | |
$2.93 | |
962.94K | |
-- | |
-- | |
$4.60 | |
$1.35 | |
-- | |
-- |
Eledon Pharmaceuticals, Inc. (ELDN) last closed at $2.93 as of 2026-09-04 23:51:00, unchanged from the previous close of $2.93.
During the latest regular trading session, ELDN traded between $1.07 and $22.91, with a volume of 962.94K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Eledon Pharmaceuticals, Inc. (ELDN) moved from $3.18 to $3.02, representing a decline of 5.04% ($0.16).
The stock traded between $2.94 and $3.06 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 1.24 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 51.2%
ELDN is currently trading at $3.02, placing it 51.2% of the way from its 52-week low of $1.35 to its 52-week high of $4.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 33 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eledon Pharmaceuticals, Inc. (ELDN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.